The pooled risk estimates indicated that TIM-3 −1516G/T polymorphism was associated with an increased risk of overall cancer (GT vs. GG: OR = 1.38, 95%CI: 1.08-1.77, Pz = 0.01; TT+GT vs. GG: OR = 1.40, 95%CI: 1.08-1.83, Pz = 0.01; T vs. G: OR = 1.39, 95%CI: 1.07-1.79, Pz = 0.01) (Figure S1). The gene discussed is HAVCR2; the disease is cancer.